Therapeutic Response

ER negative, HER2-negative, and PR negative status confers therapeutic sensitivity to Carboplatin in combination with Gemcitabine in patients with Invasive Breast Carcinoma.

Statements

Source and description
Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved gemcitabine in combination with carboplatin (AUC2) - 21 days for reimbursement as a treatment option for the treatment of locally recurrent metastatic triple negative breast cancer.